Muscular Dystrophy Canada Rare Disease Day Update
Rare Disease Day, which occurs on the last day of February (Feb 28th, 2021), is meant to raise awareness amongst the general public and decision-makers about rare diseases and their impact on individuals’ lives. This year, Rare Disease Day will look a little different around the world as we connect virtually instead of in person due to the ongoing COVID-19 pandemic.
Considering many neuromuscular conditions are considered rare, and even ultra-rare, Muscular Dystrophy Canada (MDC) will be featuring individuals with lived experience with varying neuromuscular disorders.
In the week leading up to Rare Disease Day, each day MDC will spotlight a client and their response to the question: how has it been living with a NMD in the midst of the COVID-19 pandemic? These personal stories will showcase the diversified impact of the pandemic on the quality of lives of individuals affected by neuromuscular conditions and reveal individuals’ experiences with interrupted care, increased social isolation/fatigue, frequent cancellation or postponement of treatments and clinic visits, allied health and primary care or specialist appointments, and interrupted rehabilitation and home care supports.
The stories will also highlight the resilience of individuals and their families, the benefits of virtual tele-care and programs for those with mobility challenges and the positive lessons the pandemic has offered. In addition to the personal stories, to increase awareness and knowledge of NMDs, there will be a short plain-language descriptions of the following groups that fall within MDC’s umbrella:
(1) Muscular Dystrophies
(2) Congenital Muscular Dystrophies
(3) Congenital Myopathies
(4) Auto-immune Mediated Myopathies
(5) Metabolic Myopathies
(6) Genetic and Immune-Mediated Neuromuscular Junction Disorders
(7) Hereditary Peripheral Nerve Disorders (Genetic Neuropathies)
(8) Immune-Mediated Peripheral Nerve Disorders
(9) SMA and related Disorders
For more information about Rare Disease Day, please email
Return to the February 2021 Newsletter
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.